Embodiments disclosed herein are directed to negative pressure treatment systems and wound dressing systems, apparatuses, and methods that may be used for the treatment of wounds. In particular, some embodiments are directed to improved wound dressings comprising an obscuring layer that may hide fluid contained therein. Some embodiments may further comprise one or more viewing windows disposed therethrough so as to enable monitoring or examination of fluids contained therein.

Described herein are dressings for incision management comprising a dressing layer that comprises: an elastic layer such as a hydrocolloid or foam layer; and an absorbent layer coupled, for example by lamination, to the elastic layer and which comprises: (i) from about 45% to about 90% carboxymethyl cellulose fibers; and (ii) from about 10% to about 55% elastic reinforcing fibers. Though the elastic layer may be substantially elastically deformable under tissue treatment conditions and the absorbent layer may be not elastically deformable under tissue treatment conditions, the coupling together of the elastic layer and the absorbent layer may result in a dressing layer, and advantageously a dressing, that is substantially elastically deformable under tissue treatment conditions. Methods for manufacturing such dressings and of eliminating, minimizing, or reducing edema using such dressings are also described herein.

Disclosed is a porous structure including water-soluble chitosan; and a carboxymethyl cellulose-based compound, wherein a weight ratio of the water-soluble chitosan and the carboxymethyl cellulose-based compound is from 65:35 to 25:75, and a process for preparing the same.

A tubular body is configured to be disposed around and to apply compression to an extremity. The tubular body includes a treatment area having a first filament and a second filament. Both the first filament and the second filament are disposed to engage the surface of the extremity. The first filament includes AgNP in a concentration effective to promote healing of a wound on the surface of the extremity. The second filament includes a metal having a composition that forms a galvanic couple with silver. The first filament and the second filament are arranged in the tubular body such that the AgNP and metal form galvanic couples across at least a portion of the treatment area when in the presence of a fluid in the wound of the extremity that produce an electric current in an amount effective to further promote healing of the wound.

A chemically modified cellulose/alginate co-spun (seacell) fiber, a wound dressing made therefrom and a preparation method thereof. The seacell fiber is subject to a chemical modification through which a hydrophilic carboxymethyl group is introduced into the cellulose structure making the chemically modified seacell fiber more absorbent. The modified cellulose has a degree of substitution of 0.05-0.5; the seacell fiber has a linear density of 0.5-5 dtex and a fiber length of 5-180 mm. The seacell fiber has hygroscopic and gel-forming properties, while retaining its active ingredient of algae particles.

A dressing configured to be positioned adjacent to a tissue site is disclosed herein. The dressing may include oxidized regenerated cellulose (ORC), collagen, and at least one nutrient including glutamine. Methods of treating a tissue site are also disclosed herein.

A medical delivery device for treating a tunneling wound includes an outer sleeve, a plunger, and a hollow tube extending through an opening in the plunger. The plunger is configured to deliver a wound treatment material from an inner cavity of the outer sleeve, through a cavity opening on the outer sleeve, and into the tunneling wound. The hollow tube is configured to deliver a fluid to the wound treatment material after insertion into the tunneling wound. In some embodiments, the medical delivery device may further include a flap disposed on the outer sleeve. The flap may be reconfigurable between a closed position in which the flap is configured to shield the cavity opening, and an open position in which the flap is configured to allow the wound treatment material to be ejected through the cavity opening.

The present invention relates to hemostatic scaffold compositions and the method of preparation thereof. In present invention, hemostatic scaffold compositions for wound care and dental care, uses chitosan and tranexamic acid.

Wound dressings, methods for forming the wound dressings, and methods for using the wound dressings are described. Wound dressings include a polymeric composition that includes a biocompatible polymer and a pH indicating agent. The polymeric composition can be at a wound contacting surface of a wound dressing in the form of, e.g., a fiber, a hydrogel, or a microsphere. The color of the polymeric composition as determined by the pH indicating agent can indicate the presence of infection or a chronic wound state. The wound dressings can be used for early detection of healing abnormalities in acute, chronic, or burn wounds.

This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phyto-pharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.